(All fields required)
Please enter a valid email.
Please enter your name.
Tsuyoshi Fukuda, PhD
is director of the pharmacogenetics laboratory in the Division of Clinical Pharmacology. He focuses on drug metabolizing enzyme and transporter genetic variants, PK and response to medication and adverse drug events. He has developed innovative approaches in pharmacogenetic assay development, data analyses, integrated PK/PD/PG modeling of the clinical data set, and physiologically based pharmacokinetic (PBPK) analysis and model development.
Associate Professor, UC Department of Pediatrics
Clinical pharmacology (pharmacogenetics, pharmacokinetics and pharmacodynamics)
Dr. Fukuda received his pharmacy degree and PhD in pharmaceutical science from Osaka University, Japan. He received postdoctoral training in the Division of Clinical Pharmacology and Pharmacogenomics (Prof. J. Azuma, MD) and served as an assistant professor at Osaka University, Graduate School of Pharmaceutical Sciences. He joined the Division of Clinical Pharmacology (Prof. Alexander A Vinks, PharmD, PhD) at Cincinnati Children's Hospital Medical Center in 2007. He spent over 15 years in the field of clinical pharmacology while engaged in pharmacogenetic (PG) and pharmacokinetic-pharmacodynamic (PK/PD) research. His current research interests include the clinical application of integrated PK/PD/PG modeling and simulation and physiologically based pharmacokinetic (PBPK) analysis with developmental pharmacology, focusing on improving our understanding of inter-patient differences in drug response and developing individualized dosing strategies in pediatric patients.
Dr. Fukuda’s efforts have resulted in over 50 peer-reviewed publications with project members that include master's and PhD students, research fellows, clinical fellows, pharmacists, physicians, and private sector R & D staff.
Mizuno T, Fukuda T, Masuda S, Uemoto S, Matsubara K, Inui KI, Vinks AA. Developmental trajectory of intestinal MDR1/ABCB1 expression in children. Br J Clin Pharmacol. 2013 Jul 23. [Epub ahead of print].
Emoto C, Fukuda T, Cox S, Christians U, Vinks AA. Development of a physiologically-based pharmacokinetic model for sirolimus: predicting bioavailability based on intestinal CYP3A content. CPT Pharmacometrics Syst Pharmacol. 2013 Jul 24;2:e59.
Fukuda T, Chidambaran V, Mizuno T, Venkatasubramanian R, Ngamprasertwong P, Olbrecht V, Esslinger HR., Vinks AA, Sadhasivam S. Organic Cation Transporter 1 Genetic Variants influence the pharmacokinetics of Morphine in Children. Pharmacogenomics. 2013 Jul;14(10):1141-51.
Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D. Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med. 2013 Jul;39(7):1247-52.
Shimamoto Y, Fukuda T, Tominari S, Fukumoto K, Ueno K, Dong M, Tanaka K, Shirasaka T, Komori K. Decreased vancomycin clearance in patients with congestive heart failure. Eur J Clin Pharmacol. 2013 Mar;69(3):449-57.
Fukuda T, Goebel J, Cox S, Maseck D, Zhang K, Sherbotie JR, Ellis EN, James LP, Ward RM, Vinks AA. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients. Ther Drug Monit. 2012 Dec;34(6):671-9.
Hooper DK, Fukuda T, Gardiner R, Logan B, Roy-Chaudhury A, Kirby CL, Vinks AA, Goebel J. Risk of Tacrolimus Toxicity in CYP3A5 Non-Expressors Treated with Intravenous Nicardipine After Kidney Transplantation. Transplantation. 2012 Apr 27;93(8):806-12.
Fukuda T, Brunner HI, Sagcal-Gironella AC, Vinks AA. Non-steroidal Anti-Inflammatory Drugs may reduce Enterohepatic Recirculation of Mycophenolic Acid in Patients with Childhood-onset Systemic Lupus Erythematosus. Ther Drug Monit. 2011 Oct;33(5):658-62.
Sagcal-Gironella AC, Fukuda T, Wiers T, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI. Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid and Their Relation to Response to Therapy of Childhood-onset Systemic Lupus Erythematosus. Seminars in Arthritis and Rheumatism. 2011 Feb;40(4):307-13.
Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of Mycophenolic Acid effects in Pediatric Kidney Transplant Recipients. J Clin Pharmacol. 2011 Mar;51(3):309-20.
Alexander A. Vinks, PharmD, PhD, FCP Director, Division of Clinical Pharmacology
Director, Division of Clinical Pharmacology
Professor, UC Department of Pediatrics
Professor, Adjunct Professor of Pharmacology
Dr. Vinks received his MS in pharmacology from the University of Toronto, Canada and a pharmacy degree and PhD in pharmacology from Leiden University, The Netherlands. He was trained as a hospital pharmacist (PharmD) and clinical pharmacologist at The Hague Hospitals Central Pharmacy, The Hague, The Netherlands.
Before joining the Division of Pharmacology Research at Cincinnati Children's Hospital Medical Center, he was director of the Clinical Pharmacology & Toxicology Laboratory at The Hague. Dr. Vinks has spent over 20 years in the field of therapeutic drug monitoring and applied pharmacokinetics, both in the research aspects of population pharmacokinetic studies, as well as in the clinical application of these approaches to clinical patient care.
Dr. Vinks holds an academic appointment with the University of Cincinnati College of Medicine and is the principal investigator for the Pediatric Pharmacology Research Unit (PPRU). He is director of the Laboratory of Applied Pharmacokinetics and Therapeutic Drug Management (LAP/TDM) and clinical pharmacology fellowship program at Cincinnati Children's. His current research interests include pharmacokinetic-pharmacodynamic (PK-PD) modeling and the application of population and simulation methods in TDM and clinical trial design. He has authored over 50 publications in the area of TDM, pharmacokinetics and clinical pharmacology. Dr. Vinks has been actively involved with International Association of Therapeutic Drug Monitoring and Clinical Toxicology from the beginning. He is chair of the TDM cost-effectiveness committee, serves as secretary of the Executive Board of Directors, and is on the editorial board of the journal Therapeutic Drug Monitoring. Dr. Vinks is both board certified in clinical pharmacology and toxicology and is a fellow of the American College of Clinical Pharmacology.
Certification American Board of Clinical Pharmacology, 2001.
PhD Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996.
PharmD Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986 .
MS Pharmacology, University of Toronto, Toronto Canada, 1983.
MS Pharmacy, Leiden University, Leiden, The Netherlands, 1982.
Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan 1;50(1):1-24. Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI. Pharmacokinetics and pharmacodynamics of mycophenolic Acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. Semin Arthritis Rheum. 2011 Feb;40(4):307-13. Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62. Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. J Clin Pharmacol. 2010 Apr 23. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.
Vargus-Adams JN, McMahon MA, Michaud LJ, Bean J, Vinks AA. Pharmacokinetics of amantadine in children with impaired consciousness due to acquired brain injury: preliminary findings using a sparse-sampling technique. PM R. 2010 Jan;2(1):37-42. Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29. Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94. Prausa SE, Fukuda T, Maseck D, Curtsinger KL, Liu C, Zhang K, Nick TG, Sherbotie JR, Ellis EN, Goebel J, Vinks AA. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009 May;85(5):495-500. Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008 May-Jun;22(3):281-91.
Vidya Chidambaran, MD Anesthesiologist, Department of Anesthesia
Anesthesiologist, Department of Anesthesia
Associate Professor, UC Department of Anesthesia
MBBS: Medicine,Bangalore Medical College, India, 1997
MD: Anesthesiology, Kasturba Medical College, India, 1998-2001
Internship: Anesthesiology, Jackson Memorial Hospital, Miami, Florida, 2003-2004
Residency: Anesthesiology, Brookdale University Hospital, Brooklyn, New York, 2004-2007
Fellowship: Pediatric Anesthesia, Johns Hopkins Hospital, Baltimore, Maryland, 2007-2008
S Sadhasivam, T Fukuda, V Chidambaran, T Mizuno, R Venkatasubramanian, P Ngamprasertwong, V Olbrecht, H Esslinger, A A Vinks. Organic cation Transporter 1 Genetic Variants contribute to decreased Morphine Clearances in Caucasian children. (Accepted for publication, Pharmacogenomics 2013)
V Chidambaran, S Sadhasivam, J Diepstraten, H Esslinger, S Cox, B M Schnell, P Samuels, T Inge, A A Vinks, C A Knibbe. Evaluation of propofol anesthesia in morbidly obese children and adolescents. BMC Anesthesiology 2013, 13:8.
Chidambaran V, Gentry C, Ajuba-Iwuji C, Sponsellar PD, Ain M, Lin E, Zhang X, Klaus SA, Njoku DB. Retrospective Identification of New Risk Factors for Surgical Site Infections in Cerebral Palsy Patients Following Spine Surgery. Anesth Analg. 2013 May 17. [Epub ahead of print] PMID: 23687234
Chidambaran V, Mahmoud M, Sadhasivam S. Risk for Peroneal Nerve Injury After Femur Osteosarcoma Resection: Is regional analgesia safe?Journal of clinical anesthesia. 12/2012; DOI:10.1016/j.jclinane.2012.06.013
Sadhasivam S and Chidambaran V. Pharmacogenomics of Opioids and Perioperative Pain Management. Pharmacogenomics. 11/2012; 13(15):1719-40. 3.97
V Chidambaran, S Sadhasivam. Pediatric Acute and Surgical Pain Management: Recent Advances and Future Perspectives. "Contemporary Topics in Pediatric Anesthesiology" in International Anesthesiology Clinics 2012 Fall; 50(4):66-82.
Sadhasivam S, Krekels E, Chidambaran V, Esslinger H, Zhang K, Fukuda T, Vinks AA Morphine Clearance in Children: Does Race or Genetics Matter?Journal of opioid management 07/2012; 8(4):217-226. 2012.
Chidambaran V, Rosing J, Soler X, Sadhasivam S Muscle Trauma from Tourniquet (Mis)Use. Anesthesiology, July 2012 - Volume 117 - Issue 1 - p 179.- 5.36. 2012.
Diepstraten J, Chidambaran V, Sadhasivam S, Esslinger H, Cox S, Inge T, Knibbe CAJ, Vinks AA Propofol Clearance in Morbidly Obese Children and Adolescents. Clin Pharmacokinet 06/2012; 51 (8): 543-551,- 5.40. 2012.
Sadhasivam S, Chidambaran V, Ngamprasertwong P, Esslinger H, Prows C, Zhang X, Martin LJ, McAuliffe J. Race and Unequal Burden of Perioperative Pain and Opioid Related Adverse Effects in African-American and Caucasian Children. Pediatrics. 04/2012;129:832–838 – 4.47. 2012.
Tracy A. Glauser, MD Associate Director, Cincinnati Children's Research Foundation
Associate Director, Cincinnati Children's Research Foundation
Director, Comprehensive Epilepsy Center
Co-Director, Genetic Pharmacology Service
Epilepsy; pharmacogenetics; clinical pharmacology
Clinical pharmacology; pharmacogenetics; antiepileptic clinical trials
Modi AC, Guilfoyle SM, Morita DA, Glauser TA. Development and reliability of a correction factor for parent-reported adherence to pediatric antiepileptic drug therapy. Epilepsia. 2010 Nov 18. doi: 10.1111/j.1528-1167.2010.02789.x.
Modi AC, Monahan S, Daniels D, Glauser TA. Development and validation of the Pediatric Epilepsy Medication Self-Management Questionnaire. Epilepsy Behav. 2010 May;18(1-2):94-9
Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, Clark PO, Capparelli EV, Adamson PC; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med. 2010 Mar 4;362(9):790-9.
Holland KD, Monahan S, Morita D, Vartzelis G, Glauser TA. Valproate in children with newly diagnosed idiopathic generalized epilepsy. Acta Neurol Scand. 2010 Mar;121(3):149-53.
Pestian J, Spencer M, Matykiewicz P, Zhang K, Vinks AA, Glauser T. Personalizing Drug Selection Using Advanced Clinical Decision Support. Biomed Inform Insights. 2009 Jun 23;2:19-29.
Prows CA, Nick TG, Saldaña SN, Pathak S, Liu C, Zhang K, Daniels ZS, Vinks AA, Glauser TA. Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):385-94.
Modi AC, King AS, Monahan SR, Koumoutsos JE, Morita DA, Glauser TA. Even a single seizure negatively impacts pediatric health-related quality of life. Epilepsia. 2009 Sep;50(9):2110-6.
Daniels ZS, Nick TG, Liu C, Cassedy A, Glauser TA. Obesity is a common comorbidity for pediatric patients with untreated, newly diagnosed epilepsy. Neurology. 2009 Sep 1;73(9):658-64.
Glauser TA, Sankar R; Co-chairs of the Leadership in Epilepsy, Advocacy, and Development Faculty. Core elements of epilepsy diagnosis and management: expert consensus from the Leadership in Epilepsy, Advocacy, and Development (LEAD) faculty. Curr Med Res Opin. 2008 Dec;24(12):3463-77.
Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008 May 20;70(21):1950-8.
Senthilkumar Sadhasivam, MD, MPH
MBBS: Thanjavur Medical College, India, 1993.
MD: AIIMS, New Delhi, India, 1999.
Residency: Beth Israel Deaconess Medical Center, Harvard University, Boston, MA.
Fellowship: Children's Hospital of Philadelphia, 2004.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2014 Cincinnati Children's Hospital Medical Center